List of Excipients in Branded Drug CORPHEDRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Pharmaceutical Inc	CORPHEDRA	ephedrine sulfate	42023-196	WATER

CorPhedra Excipient Strategy and Commercial Opportunities for Ephedrine Sulfate Injection

Last updated: September 1, 2026

CorPhedra is a preservative-free ephedrine sulfate injection for the rapid treatment of clinically significant hypotension occurring in the setting of anesthesia. Its commercial position is defined by a simple aqueous formulation, concentrated 50 mg/mL presentation, single-dose vial packaging, and hospital demand for predictable, ready-to-administer vasopressors. The strongest excipient opportunities are not new active-ingredient claims. They are improved dilution stability, ready-to-use presentations, reduced preparation risk, container-closure performance, and supply-chain differentiation.

What is CorPhedra and how is it formulated?

CorPhedra contains ephedrine sulfate for intravenous administration. The product is supplied as a sterile, preservative-free solution in a single-dose vial at a concentration of 50 mg/mL. The labeled indication is treatment of clinically significant hypotension during anesthesia. [1]

Attribute	CorPhedra profile
Active ingredient	Ephedrine sulfate
Therapeutic class	Sympathomimetic vasopressor
Route	Intravenous
Labeled strength	50 mg/mL
Dosage form	Sterile injectable solution
Preservative status	Preservative-free, single-dose presentation
Primary use setting	Operating rooms, anesthesia, procedural care
Administration	Dilution and intravenous administration according to labeling
FDA pathway	Approved drug product under NDA 208289
Formulation complexity	Low excipient count, high sterility and stability burden

Which excipients are used in CorPhedra?

The CorPhedra labeling identifies water for injection as the principal vehicle and indicates pH adjustment with sodium hydroxide and/or sulfuric acid. The product is designed as a simple aqueous solution rather than an emulsion, suspension, lyophilized cake, or multidose preserved product. [1]

The excipient strategy has several technical implications:

1. The formulation minimizes excipient-related tolerability concerns for intravenous use.
2. The absence of antimicrobial preservatives supports single-dose administration and reduces exposure to benzyl alcohol, parabens, phenol, or related preservatives.
3. pH adjustment is likely central to chemical stability, solubility, and compatibility with the container-closure system.
4. The concentrated solution shifts part of the handling burden to the hospital, where dilution may be required before administration.

The commercial value is therefore concentrated in presentation design and use-process improvement rather than in a complex excipient platform.

What is the commercial role of excipients in CorPhedra?

Excipients can support four commercial objectives for an ephedrine injection:

• Maintain assay and impurity control during labeled storage.
• Prevent precipitation, discoloration, or pH drift.
• Reduce adsorption or extractables from the primary container.
• Enable a differentiated ready-to-use or premixed product.

For an injectable vasopressor, a small improvement in preparation reliability can have more value than a nominal reduction in material cost. Anesthesia departments prioritize rapid access, dose accuracy, sterility assurance, and avoidance of medication errors. Those priorities make formulation and packaging part of the product’s commercial proposition.

Why does the preservative-free design matter?

Preservative-free presentation is commercially relevant because ephedrine is administered intravenously in acute-care settings. A single-dose, preservative-free vial can be positioned for operating-room use where:

• The product is drawn up shortly before administration.
• The dose is administered to one patient.
• Repeated access to a multidose container is unnecessary.
• Hospitals seek to reduce preservative exposure and contamination risk.

The trade-off is higher packaging and unit-dose cost, together with a shorter practical in-use period after opening. A competing product with a lower price but more preparation steps may still lose preference if it creates additional workflow burden.

What formulations are protected by CorPhedra’s excipient strategy?

Publicly available product information supports a formulation strategy based on an aqueous, preservative-free ephedrine sulfate solution. The principal defensible technical attributes are likely to be:

Potential protection area	Commercial relevance	Likely regulatory value
Ephedrine sulfate concentration	High	Supports product identity and dosing
pH range	High	Supports stability and compatibility
Low particulate burden	High	Critical for injectable quality
Preservative-free formulation	Medium to high	Supports operating-room positioning
Container-closure configuration	High	Supports sterility and shelf life
Diluted solution stability	High	Enables ready-to-use or premixed products
Syringe or vial presentation	High	Reduces preparation steps
Manufacturing process controls	High	Protects reproducibility and supply reliability

The simplest CorPhedra formulation has limited room for classic excipient patenting. A patent claim directed only to water for injection, pH adjustment, and ephedrine sulfate would face substantial prior-art risk because aqueous ephedrine injections have long been known. Stronger intellectual-property positions would require a specific technical result, such as:

• Extended stability at a defined concentration and temperature.
• Reduced oxidation or impurity formation.
• A defined pH range linked to unexpected stability.
• Compatibility with a specific polymer syringe or vial.
• A ready-to-use diluted formulation with a defined shelf life.
• A low-volume formulation that reduces dosing or preparation errors.
• A terminal sterilization process compatible with the formulation.

When does CorPhedra lose exclusivity?

CorPhedra contains an established active ingredient, ephedrine sulfate. Market exclusivity is therefore driven primarily by generic competition, product-specific regulatory rights, manufacturing economics, and supply availability rather than by a new-molecule period.

Exclusivity factor	CorPhedra assessment
New chemical entity exclusivity	Not applicable to established ephedrine sulfate
Orphan exclusivity	Not indicated for the anesthesia hypotension indication
Pediatric exclusivity	No product-specific extension identified in the core public labeling
Patent-based exclusivity	Requires confirmation against the current Orange Book
Generic pathway	ANDA competition is commercially plausible
Biosimilar exposure	Not applicable; CorPhedra is a small-molecule injectable
Main barrier to entry	Sterile manufacturing, quality systems, market economics, and supply reliability

A fixed patent-expiration date should not be assigned without a current Orange Book record and any associated patent litigation docket. The product’s commercial protection should be analyzed as a combination of listed patents, regulatory exclusivity, ANDA status, and manufacturing capacity.

What is the Orange Book status of CorPhedra?

CorPhedra is associated with NDA 208289 in FDA drug-product records. The Orange Book is the controlling source for any listed patents, therapeutic-equivalence ratings, reference-listed-drug status, and applicant information. [2]

For business planning, the relevant questions are:

1. Is CorPhedra designated as the reference listed drug for a particular strength and dosage form?
2. Are any patents listed against the NDA?
3. Are the patents formulation, method-of-use, or packaging patents?
4. Have any Paragraph IV certifications been filed?
5. Has FDA assigned a therapeutic-equivalence rating to competing ephedrine sulfate injections?

Because ephedrine sulfate has long-established injectable products, an ANDA sponsor may be able to rely on a suitability or bioequivalence pathway appropriate to the product. Injectable solutions generally face a more straightforward bioequivalence analysis than orally administered products, but the sponsor must still address inactive ingredients, concentration, route, sterility, particulate matter, container closure, and labeling.

Which companies are challenging CorPhedra?

The relevant competitive field includes manufacturers of ephedrine sulfate injection, hospital suppliers, outsourcing facilities, and companies offering compounded or ready-to-use vasopressor products. Competition may arise even without a publicly reported patent challenge.

Competitor category	Competitive mechanism	Risk to CorPhedra
ANDA manufacturers	Lower-priced therapeutically equivalent injection	High
Established generic injectables	Existing hospital contracts and broad portfolios	High
503B outsourcing facilities	Ready-to-use syringes and diluted presentations	Medium to high
Contract manufacturers	Flexible supply and private-label products	Medium
Alternative vasopressors	Phenylephrine, norepinephrine, and other agents	Medium
Automated compounding platforms	Reduced in-hospital preparation burden	Medium

A Paragraph IV challenge would be relevant only if the Orange Book identifies an enforceable patent. In practice, a generic sponsor may also pursue a Paragraph III certification, a non-infringement position, or an ANDA strategy that avoids the claimed formulation or use. No biosimilar pathway applies because ephedrine sulfate is a chemically synthesized small molecule, not a biologic.

What excipient-based commercial opportunities exist for CorPhedra?

Ready-to-use diluted ephedrine syringes

The most direct opportunity is a prefilled syringe containing a clinically convenient diluted concentration. Hospitals could avoid drawing concentrated 50 mg/mL product into a syringe and performing bedside dilution.

Potential advantages include:

• Lower dose-calculation risk.
• Faster administration during anesthesia.
• Reduced manipulation of a sterile product.
• Easier stocking in anesthesia carts.
• Better alignment with barcode medication administration.
• Potential reduction in discarded residual drug.

A ready-to-use syringe would require a new stability package, extractables and leachables assessment, syringe compatibility testing, particulate testing, and a validated sterile manufacturing process. The excipient system may remain simple, but the container and closure become central technical variables.

Multiple strengths

A two-strength portfolio could target different users:

Presentation	Intended use
50 mg/mL vial	Hospital dilution and institutional protocols
5 mg/mL or another diluted strength	Direct administration and reduced preparation
Prefilled syringe	Rapid operating-room use
Pharmacy bulk or controlled-access presentation	Institutional compounding workflows

The commercial value depends on avoiding confusion between concentrations. Label color, syringe design, barcode controls, and restricted stocking can be as important as the formulation itself.

Improved diluted-solution stability

A formulation with demonstrated stability after dilution could support a hospital-prepared or manufacturer-prepared product. The relevant studies would examine:

• Dilution in 0.9% sodium chloride and 5% dextrose.
• Stability in polypropylene syringes and polycarbonate containers.
• Chemical degradation and impurity formation.
• pH drift.
• Visible and subvisible particulates.
• Adsorption to syringe materials.
• Stability under refrigerated and room-temperature conditions.
• In-use duration after withdrawal or opening.

The strongest commercial claim would be a defined, validated period of stability that supports pharmacy batching or operating-room stocking.

Low-volume concentrated presentations

The existing concentrated vial minimizes volume but requires dilution. A differentiated low-volume product could be positioned for transport, emergency kits, and anesthesia carts. This opportunity has a narrower market than a ready-to-use syringe but may offer lower manufacturing and shipping costs.

Preservative-free multidose alternatives

A preserved multidose product could reduce packaging cost and improve dose availability in some institutional settings. It would also create additional risks involving preservative tolerability, multidose sterility, repeated vial access, and compliance with hospital policies. This is a weaker opportunity than a preservative-free single-dose or prefilled-syringe strategy because the principal use environment favors rapid, patient-specific administration.

How strong is the patent estate for CorPhedra?

The apparent patent strength is limited unless product-specific patents cover a defined formulation, container, stability profile, or method of use. Ephedrine sulfate itself is old, and broad claims to an aqueous injectable solution would encounter substantial prior art.

Patent layer	Expected strength
Active ingredient	Very weak; long-established compound
Basic aqueous formulation	Weak unless tied to a narrow technical result
Preservative-free formulation	Moderate only with unexpected stability or safety data
Diluted ready-to-use formulation	Potentially moderate to strong if narrowly claimed
Prefilled syringe/container system	Moderate if compatibility and stability are demonstrated
Manufacturing process	Moderate where process controls produce a measurable quality advantage
Method of treating anesthesia-related hypotension	Usually limited by established medical use and prior art
Packaging and workflow claims	Commercially useful but vulnerable to design-around

A defensible strategy would combine patent filings with trade secrets covering sterilization cycles, filling parameters, container selection, headspace control, and impurity specifications. Regulatory exclusivity may be less important than maintaining dependable supply and securing hospital contracts.

What FDA regulatory issues affect new CorPhedra presentations?

A new concentration, syringe, dilution, or container may require a supplemental NDA, a new NDA, or an ANDA depending on the sponsor’s relationship to the reference product and the extent of formulation and presentation changes. FDA review would focus on:

• Active and inactive ingredient identity.
• Sterility assurance.
• Bacterial endotoxin limits.
• Particulate matter.
• Container-closure integrity.
• Extractables and leachables.
• Stability and in-use dating.
• Labeling and concentration differentiation.
• Human factors for prefilled syringes.
• Compatibility with administration devices.
• Dose-delivery accuracy.

The formulation should avoid unnecessary excipients. Each added component creates a new qualification burden and may complicate injectable safety assessment. A practical development program would first evaluate whether the existing vehicle and pH system can support the desired presentation before introducing buffers, antioxidants, chelators, surfactants, or tonicity agents.

What generic launch risks exist for CorPhedra?

Generic entry is technically feasible, but commercial success depends on more than FDA approval.

Manufacturing and supply barriers

Sterile injectables require validated aseptic processing, skilled operators, environmental monitoring, container-closure controls, and reliable access to sterile components. Shortages of vials, elastomeric stoppers, glass, or contract manufacturing capacity can delay launch.

Market-size constraints

Ephedrine sulfate injection is a focused hospital product. A generic sponsor may face limited annual demand, contract-driven pricing, and competition from suppliers with established injectable portfolios. The product is more attractive when bundled with other anesthesia and emergency-care products.

Institutional switching barriers

Hospitals may prefer products already integrated into:

• Anesthesia medication carts.
• Electronic formularies.
• Barcode systems.
• Automated dispensing cabinets.
• Group purchasing contracts.
• Standardized dilution protocols.

A new formulation must provide a clear operational advantage or a meaningful supply and price benefit.

Shortage-driven opportunity

Supply disruptions can create rapid demand for alternate manufacturers. FDA’s drug-shortage database and ASHP shortage reporting are important indicators for launch timing and purchasing behavior. [3,4] A supplier that can offer an interchangeable vial, a ready-to-use syringe, or reliable allocation may capture share even without a superior patent position.

How does CorPhedra compare with competing vasopressors?

Product category	Main strength	Excipient opportunity	Commercial threat
Ephedrine sulfate injection	Rapid treatment of anesthesia-related hypotension with heart-rate effects	Ready-to-use diluted syringe	Direct generic competition
Phenylephrine injection	Common alternative for vasodilatory hypotension	Premixed syringes and bags	Substitution in protocols
Norepinephrine injection	Broad critical-care use	Stable premixed infusion bags	Higher-acuity substitution
Epinephrine injection	Emergency and resuscitation use	Prefilled syringe platforms	Different clinical indication
Vasopressor compounded syringes	Workflow convenience	Outsourcing and batch stability	Price and availability pressure

CorPhedra’s most defensible commercial position is not broad therapeutic differentiation. It is dependable access to a preservative-free ephedrine presentation that reduces preparation burden while preserving familiar clinical use.

What licensing deals could create value?

Potential licensing targets include:

1. A prefilled-syringe platform with validated sterile filling and device compatibility.
2. A polymer or elastomer container system that reduces adsorption and extractables.
3. A contract manufacturing arrangement for low-volume sterile injectables.
4. A hospital-pharmacy technology provider that supports barcode and automated dispensing integration.
5. A formulation platform that extends diluted-solution stability.
6. A regional distributor with operating-room and anesthesia purchasing relationships.

The highest-value deal structure would likely combine formulation know-how, manufacturing capacity, and commercial distribution. A license limited to a broad ephedrine formulation patent would have less value because of prior-art and design-around concerns.

Key Takeaways

• CorPhedra is a preservative-free, aqueous ephedrine sulfate injection supplied at 50 mg/mL for anesthesia-related hypotension.
• Its core excipient system is simple, with water for injection and pH adjustment identified in the labeling.
• The strongest commercial opportunity is a ready-to-use diluted syringe or other presentation that reduces bedside preparation.
• Stability after dilution, syringe compatibility, particulate control, and container-closure integrity are the key technical workstreams.
• Ephedrine sulfate has no biosimilar risk because it is a small-molecule active ingredient.
• Generic entry is commercially plausible, although sterile manufacturing, shortage dynamics, contracting, and hospital workflow integration affect launch economics.
• Broad patents covering ephedrine sulfate injection are likely weak. Narrow patents covering stability, concentration, container systems, or ready-to-use presentations would be more defensible.
• The Orange Book record for NDA 208289 should control any final assessment of listed patents, certifications, and regulatory exclusivity.
• Licensing value is highest in prefilled-syringe technology, sterile manufacturing capacity, and hospital distribution rather than in basic excipient composition.

FAQs About CorPhedra Excipient and Commercial Strategy

Can CorPhedra be reformulated with a buffer?

Potentially, but a buffer is not automatically commercially beneficial. The sponsor would need to demonstrate improved stability, compatibility, or manufacturing control that justifies the additional injectable-excipient qualification burden.

Is CorPhedra suitable for a 503B ready-to-use syringe strategy?

The active ingredient and acute-care use case are compatible with a 503B outsourcing concept, but the business would depend on applicable federal requirements, state law, stability data, sterile-process capacity, and hospital purchasing contracts.

What is the strongest formulation patent opportunity for ephedrine injection?

A narrow claim covering a stable diluted concentration in a defined container, with validated chemical and physical stability over a specified period, is stronger than a broad claim to ephedrine sulfate in water.

Could CorPhedra compete through a lower-cost vial?

Yes. A lower-cost vial could gain share through group purchasing contracts, but price competition alone is vulnerable to generic entry. Supply reliability and product availability may provide greater commercial leverage.

Does CorPhedra face biosimilar competition?

No. Biosimilar regulation applies to biological products. CorPhedra contains ephedrine sulfate, a chemically synthesized small-molecule drug, so competition would generally arise through generic injectable products and alternative vasopressors.

References

1. U.S. Food and Drug Administration. (n.d.). CorPhedra (ephedrine sulfate) injection prescribing information, NDA 208289.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Drug shortages database.

4. American Society of Health-System Pharmacists. (n.d.). ASHP drug shortages resource center.